ReviewNeuropsychiatric disease and treatment2026
Home-Based Transcranial Direct Current Stimulation for Depression: From Feasibility to Clinical Implementation.
Review in Neuropsychiatric disease and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Home-based transcranial direct current stimulation (tDCS) for major depressive disorder (MDD) has progressed from early feasibility studies to an approved clinical treatment, highlighted by the US Food and Drug Administration's 2025 premarket approval of the Flow FL-100 device. This milestone shifts the field from asking whether home-based tDCS can be delivered safely and effectively to defining how it should be implemented in routine clinical practice. This review synthesizes the current evidence on treatment outcomes, adherence, and safety, with an emphasis on factors that determine successful real-world implementation. Randomized controlled trials support the efficacy of home-based tDCS when delivered using adequate cumulative dosing, structured treatment protocols, and appropriate supervision or adherence monitoring. In contrast, shorter-duration and fully unsupervised protocols have generally shown less favorable outcomes, although the independent contributions of dose, treatment duration, and supervision remain difficult to disentangle. High adherence has been reported with user-centered device design, standardized training, remote monitoring, and scalable supervision models that maintain treatment fidelity while supporting broad clinical deployment. Home-based tDCS has demonstrated an excellent safety profile when delivered using standardized equipment, structured protocols, and active monitoring, exemplified by more than 30,000 supervised home-based sessions delivered through a large academic clinical program without reported skin lesions or serious adverse events attributable to tDCS. Remaining priorities include optimizing acute and maintenance dosing strategies, identifying predictors and biomarkers of response, defining the role of paired behavioral interventions, personalizing treatment for special populations - including perinatal patients, older adults, and adolescents - and integrating home-based tDCS within interventional psychiatry care pathways. The evidence supports a transition from proof-of-concept to clinical implementation, with future research focused on optimizing delivery, personalizing treatment, and expanding access to evidence-based neuromodulation for depression.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.